Artiva Biotherapeutics (NASDAQ:ARTV) CEO Fred Aslan Sells 23,429 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 23,429 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $10.92, for a total transaction of $255,844.68. Following the completion of the sale, the chief executive officer directly owned 1,449,765 shares of the company’s stock, valued at $15,831,433.80. The trade was a 1.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Artiva Biotherapeutics Stock Down 0.8%

Shares of NASDAQ:ARTV opened at $10.79 on Thursday. The company has a market capitalization of $527.52 million, a price-to-earnings ratio of -3.27 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a 52 week low of $2.22 and a 52 week high of $14.53. The firm has a 50 day moving average of $10.64 and a 200 day moving average of $8.92.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.63). On average, sell-side analysts expect that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ARTV shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Institutional Trading of Artiva Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new position in shares of Artiva Biotherapeutics in the second quarter worth about $144,000. Spark Investment Management LLC purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $160,000. Alyeska Investment Group L.P. grew its holdings in Artiva Biotherapeutics by 173.6% in the second quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock valued at $2,654,000 after purchasing an additional 173,615 shares during the period. Nantahala Capital Management LLC acquired a new stake in Artiva Biotherapeutics in the second quarter valued at approximately $2,910,000. Finally, 5AM Venture Management LLC purchased a new stake in shares of Artiva Biotherapeutics in the second quarter valued at approximately $22,827,049.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.